Common stock, par value $0.001 per share
- Symbol
- RNA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Atrium Therapeutics, Inc.
RNANASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On October 27, 2026, Atrium Therapeutics, Inc. (the “Company”) issued a press release announcing that the first patient has been dosed in the Company’s Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (“PRKAG2”) syndrome.…
Company context
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company’s proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to
Current securities
Registered securities in this filing
Atrium Therapeutics, Inc. · 8-K · Filed 2026-10-27
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On October 27, 2026, Atrium Therapeutics, Inc. (the “Company”) issued a press release announcing that the first patient has been dosed in the Company’s Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (“PRKAG2”) syndrome.
A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome - Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants - - Initial proof of concept data expected in second half of 2027 - SAN DIEGO, Oct. 27, 2026 - Atrium Therapeutics, Inc. (Nasdaq: RNA) (the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome. The Company expects to report initial proof-of-concept data from Corventis in the second half of 2027. “Dosing the first patient in the Corventis clinical trial is a milestone for Atrium and, more importantly, for the PRKAG2 community. This is the first clinical trial for people living with PRKAG2 syndrome evaluating a potential treatment for the underlying cause of the disease. It is also an important step for the broader genetic cardiomy…
Open exhibit ↗